SynthesisInternational urology and nephrology2026
Organ-sparing radiotherapy in penile cancer: therapeutic approaches.
Synthesis in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectiveThe primary treatment for penile squamous cell carcinoma (PSCC) is often partial or total penectomy, which causes significant functional morbidity and psychological distress. Brachytherapy (BT) has emerged as a primary, organ-preserving alternative. The objective of this systematic review was to analyze the oncologic efficacy, organ preservation rates, and functional outcomes of LDR, PDR, and HDR brachytherapy.
methodsThis systematic review (PROSPERO: CRD420251136499) followed PRISMA guidelines. We searched PubMed, Scopus, ScienceDirect, and Google Scholar (to August 2025) for studies (n ≥ 10) reporting clinical outcomes of LDR, PDR, or HDR brachytherapy for adult penile cancer. Risk of bias was assessed using NIH tools and the Cochrane RoB tool. Due to high heterogeneity in study design and treatment techniques, a quantitative synthesis (narrative) was performed.
resultsEighteen studies were included. Five-year cancer-specific survival (CSS) ranged from 85.0 to 100% across 9 studies that explicitly reported this metric. Local failures, when they occurred, were demonstrated to be highly salvageable (77-100% success).
conclusionsThe evidence, though limited and highly heterogeneous, confirms that penile brachytherapy is an effective, curative-intent, organ-sparing treatment for T1-T2 disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.